Prospective analysis of circulating metabolites and endometrial cancer risk.

Aged Biomarkers, Tumor / blood Body Mass Index Carnitine / blood Case-Control Studies Endometrial Neoplasms / blood Female Glycine / blood Humans Metabolomics Middle Aged Prospective Studies Risk Factors Serine / blood Sphingomyelins / blood
Amino acids Endometrial cancer Lipids Metabolomics Obesity

Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
08 2021
Historique:
received: 22 02 2021
accepted: 01 06 2021
pubmed: 9 6 2021
medline: 15 12 2021
entrez: 8 6 2021
Statut: ppublish

Résumé

Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from 853 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC). A total of 129 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed. After adjustment for body mass index, sphingomyelin [SM] C18:0 was positively (OR These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.

Sections du résumé

BACKGROUND
Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from 853 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC).
METHODS
A total of 129 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed.
RESULTS
After adjustment for body mass index, sphingomyelin [SM] C18:0 was positively (OR
CONCLUSION
These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.

Identifiants

DOI: 10.1016/j.ygyno.2021.06.001 PMID: 34099314 PMC: PMC8336647
pubmed: 34099314
pii: S0090-8258(21)00447-9
doi: 10.1016/j.ygyno.2021.06.001
pmc: PMC8336647
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Sphingomyelins 0
Serine 452VLY9402
Carnitine S7UI8SM58A
Glycine TE7660XO1C

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-481

Subventions

Organisme : Cancer Research UK
ID : C19335/A21351
Pays : United Kingdom

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Références

Amino Acids. 2013 Sep;45(3):463-77
pubmed: 23615880
Eur J Cancer. 2018 Dec;105:103-113
pubmed: 30445359
Carcinogenesis. 2009 May;30(5):745-52
pubmed: 19279183
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):921-9
pubmed: 18398032
Int J Obes (Lond). 2014 Nov;38(11):1388-96
pubmed: 24608922
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
Sci Rep. 2020 Oct 19;10(1):17616
pubmed: 33077739
Int J Cancer. 2020 Feb 1;146(3):720-730
pubmed: 30951192
Front Endocrinol (Lausanne). 2018 Mar 12;9:87
pubmed: 29593653
JAMA Cardiol. 2019 Dec 1;4(12):1270-1279
pubmed: 31664431
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Diabetes. 2013 Feb;62(2):639-48
pubmed: 23043162
Arch Physiol Biochem. 2009 May;115(2):86-96
pubmed: 19485704
PLoS One. 2015 Aug 14;10(8):e0135437
pubmed: 26274920
PLoS One. 2011;6(6):e21103
pubmed: 21698256
Ann Clin Biochem. 2008 Nov;45(Pt 6):585-92
pubmed: 18782814
Pharmacol Rep. 2016 Jun;68(3):570-81
pubmed: 26940196
Mol Cells. 2015 Jul;38(7):587-96
pubmed: 26072981
Int J Mol Sci. 2020 Feb 16;21(4):
pubmed: 32079087
Circulation. 2012 May 8;125(18):2222-31
pubmed: 22496159
J Clin Endocrinol Metab. 2012 Sep;97(9):3216-23
pubmed: 22730518
Cancer Sci. 2018 Apr;109(4):1032-1043
pubmed: 29436067
IUBMB Life. 2017 Aug;69(8):578-594
pubmed: 28653367
Endocr Relat Cancer. 2010 Oct 29;17(4):1007-19
pubmed: 20843938
J Racial Ethn Health Disparities. 2016 Oct 17;:
pubmed: 27753051
Eur J Cancer. 2005 Sep;41(14):2155-9
pubmed: 16046115
Crit Rev Oncol Hematol. 2012 Oct;84(1):1-7
pubmed: 22429650
Cell Metab. 2017 Jan 10;25(1):43-56
pubmed: 28094011
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
JCI Insight. 2019 Jun 4;5:
pubmed: 31162145
J Proteome Res. 2018 Feb 2;17(2):804-812
pubmed: 29235868
Nat Rev Cancer. 2016 Oct;16(10):650-62
pubmed: 27634448
Nat Med. 2011 Apr;17(4):448-53
pubmed: 21423183
Diabetologia. 2018 Jan;61(1):117-129
pubmed: 28936587
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43
pubmed: 12496040
J Natl Cancer Inst. 2018 Jun 1;110(6):588-597
pubmed: 29325144
J Proteome Res. 2017 Sep 1;16(9):3137-3146
pubmed: 28758405
BMC Med. 2019 Sep 24;17(1):178
pubmed: 31547832
Biochim Biophys Acta. 2014 May;1841(5):692-703
pubmed: 24355909
J Steroid Biochem Mol Biol. 2018 Apr;178:312-321
pubmed: 29360580
Stat Interface. 2013;6(1):
pubmed: 24376905
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Stat Softw. 2014 Jul;58(12):
pubmed: 26257587
Prostaglandins Other Lipid Mediat. 2010 Jun;92(1-4):62-6
pubmed: 20226264
Front Oncol. 2016 Apr 14;6:89
pubmed: 27148481
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Int J Cancer. 2016 Jan 15;138(2):348-60
pubmed: 26238458
Nat Commun. 2019 Mar 5;10(1):1060
pubmed: 30837465
J Natl Cancer Inst. 2020 Jun 1;112(6):628-636
pubmed: 31593240
Int J Clin Oncol. 2014 Apr;19(2):364-72
pubmed: 23700142

Auteurs

Laure Dossus (L)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France. Electronic address: dossusl@iarc.fr.

Eirini Kouloura (E)

Cancer Metabolism and Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK; European Food Safety Authority, Via Carlo Magno 1A, 43126 Parma, Italy.

Carine Biessy (C)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Vivian Viallon (V)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Alexandros P Siskos (AP)

Cancer Metabolism and Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK.

Niki Dimou (N)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Sabina Rinaldi (S)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Melissa A Merritt (MA)

Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.

Naomi Allen (N)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Renee Fortner (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Elisabete Weiderpass (E)

Office of the Director, International Agency for Research on Cancer, Lyon, France.

Inger T Gram (IT)

Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Troms, Norway.

Joseph A Rothwell (JA)

Centre for Research in Epidemiology and Population Health, CESP, Université Paris-Saclay, UVSQ, Inserm U1018, Villejuif, France; Gustave Roussy, Villejuif, France.

Lucie Lécuyer (L)

Centre for Research in Epidemiology and Population Health, CESP, Université Paris-Saclay, UVSQ, Inserm U1018, Villejuif, France; Gustave Roussy, Villejuif, France.

Gianluca Severi (G)

Centre for Research in Epidemiology and Population Health, CESP, Université Paris-Saclay, UVSQ, Inserm U1018, Villejuif, France; Gustave Roussy, Villejuif, France; Department of Statistics, Computer Science and Applications "G. Parenti" (DISIA), University of Florence, Italy.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.

Therese Haugdahl Nøst (TH)

Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Troms, Norway.

Marta Crous-Bou (M)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Barcelona, Spain; Nutrition and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,USA.

Maria-Jose Sánchez (MJ)

Escuela Andaluza de Salud Pública (EASP), Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.

Pilar Amiano (P)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain.

Sandra M Colorado-Yohar (SM)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.

Aurelio Barricarte Gurrea (AB)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Navarra Public Health Institute, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA) Pamplona, Spain.

Julie A Schmidt (JA)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Domenico Palli (D)

Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Cancer Risk Factors and Life-Style Epidemiology Unit, Florence, Italy.

Claudia Agnoli (C)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provincial Health Authority (ASP) Ragusa, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.

Amalia Mattiello (A)

Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.

Roel Vermeulen (R)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.

Alicia K Heath (AK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Sofia Christakoudi (S)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; MRC Centre for Transplantation, King's College London, London, UK.

Konstantinos K Tsilidis (KK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

Ruth C Travis (RC)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Marc J Gunter (MJ)

Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.

Hector C Keun (HC)

Cancer Metabolism and Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Prospective analysis of circulating...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Prospective analysis of circulating...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Biométrie › Anthropométrie › Indice de masse corporelle › Prospective analysis of circulating...
questionsmedicales.fr › Composés chimiques organiques › Amines › Composés de triméthyl-ammonium › Carnitine › Prospective analysis of circulating...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Prospective analysis of circulating...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital féminin › Tumeurs de l'utérus › Tumeurs de l'endomètre › Prospective analysis of circulating...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Glycine › Prospective analysis of circulating...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prospective analysis of circulating...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Métabolomique › Prospective analysis of circulating...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Prospective analysis of circulating...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Prospective analysis of circulating...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Prospective analysis of circulating...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés neutres › Sérine › Prospective analysis of circulating...
questionsmedicales.fr › Lipides › Lipides membranaires › Sphingolipides › Glycosphingolipides › Glycosphingolipides neutres › Sphingomyéline › Prospective analysis of circulating...